C12N 2310/10
Type of nucleic acid
C12N2310/10 (Type of nucleic acid) appears on 14,042 US grants and 29,738 published applications in this corpus.
Search patents in C12N- Granted patents
- 14,042
- Published applications
- 29,738
- Assignees
- 5,601
- Inventors
- 37,707
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 2 | 0 |
| 1990 | 1 | 0 |
| 1991 | 4 | 0 |
| 1992 | 7 | 0 |
| 1993 | 14 | 0 |
| 1994 | 7 | 0 |
| 1995 | 20 | 0 |
| 1996 | 33 | 0 |
| 1997 | 94 | 0 |
| 1998 | 128 | 0 |
| 1999 | 113 | 0 |
| 2000 | 109 | 0 |
| 2001 | 93 | 14 |
| 2002 | 87 | 101 |
| 2003 | 65 | 274 |
| 2004 | 61 | 335 |
| 2005 | 28 | 475 |
| 2006 | 70 | 429 |
| 2007 | 66 | 516 |
| 2008 | 83 | 476 |
| 2009 | 188 | 781 |
| 2010 | 308 | 845 |
| 2011 | 366 | 860 |
| 2012 | 466 | 862 |
| 2013 | 495 | 847 |
| 2014 | 571 | 932 |
| 2015 | 680 | 1263 |
| 2016 | 692 | 1363 |
| 2017 | 764 | 1276 |
| 2018 | 857 | 1535 |
| 2019 | 948 | 1702 |
| 2020 | 940 | 1808 |
| 2021 | 994 | 2050 |
| 2022 | 980 | 2212 |
| 2023 | 923 | 2251 |
| 2024 | 946 | 2444 |
| 2025 | 1024 | 2379 |
| 2026 | 815 | 1708 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2310/14Interfering nucleic acids [na]Indexing code7,098
- C12N 2310/11AntisenseIndexing code4,701
- C12N 2310/20Involving clustered regularly interspaced short palindromic repeats [crispr]Indexing code2,683
- C12N 2310/16AptamersIndexing code1,304
- C12N 2310/12Catalytic nucleic acidsIndexing code871
- C12N 2310/17Immunomodulatory nucleic acidsIndexing code425
- C12N 2310/13DecoysIndexing code371
- C12N 2310/15Nucleic acids forming more than 2 strandsIndexing code236
All 9 subgroupsShow fewer
Recent patents
- Method for optimized RIG-I ligands6 Oct 2026US 12,751,965 B2
- ß-amyloid cyclic ribonucleic acid, polypeptide, and application thereof6 Oct 2026US 12,753,215 B2
- Methods and compositions for promoting survival and proliferation of endothelial cells and stimulating angiogenesis6 Oct 2026US 12,753,384 B2Cornell Research Foundation, Inc.
- Prime editor system for in vivo genome editing6 Oct 2026US 12,753,397 B2University of Massachusetts
- CRISPR-mediated directed codon re-write6 Oct 2026US 12,753,398 B2Limagrain Europe S.A.
- Humanized ace2-expressing transgenic mouse susceptible to sars-cov-2 virus infection and method for producing same8 Oct 2026US 2026/0305587 A1Seoul National University R&Db Foundation
- Methods and compositions for microbial delivery of double stranded rna8 Oct 2026US 2026/0305618 A1Rnaissance AG LLC
- Composition and Method for Topical Trans-spinal Delivery of Nucleic Acids and Small Molecules8 Oct 2026US 2026/0306414 A13P Biotechnologies, Inc.
- Methods of preventing on-target genotoxicity induced by nucleases8 Oct 2026US 2026/0306552 A1Chu De Bordeaux
- Modular platform for molecular conjugation8 Oct 2026US 2026/0306645 A1CamBrixBio Ltd
Most cited
By later US patents
- CRISPR-Cas systems and methods for altering expression of gene products1,186US 8,697,359 B1Massachusetts Institute of Technology · 2014
- Genetic inhibition by double-stranded RNA1,185US 6,506,559 B1Carnegie Institute of Washington · 2003
- Transgenic non-human animals capable of producing heterologous antibodies950US 5,770,429 AGenPharm International, Inc. · 1998
- Methods for identifying nucleic acid ligands856US 5,270,163 AUniversity Research Corporation · 1993
- Peptide nucleic acids763US 5,539,082 A1996